Professor David Potter (Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA) discusses the results of the I-SPY 2 trial, the evaluation of tucatinib + (paclitaxel + pertuzumab + trastuzumab) in high-risk HER2 positive stage II/III breast cancer. These results were presented at the San Antonio Breast Cancer Symposium 2021.
Question: Please can you summarise the aims, design, eligibility criteria and the efficacy and safety findings of the I-SPY 2 trial?
Speaker Disclosure: David Potter reports grants from Quantum Leap Healthcare Collaborative and Seagen during the conduct of the study, as well as grants from Department of Defense, ImmunoMet Therapeutics, Pfizer, Innocrin, Takeda, Nektar Therapeutics, Roche, AstraZeneca, Spectrum Pharmaceuticals, Huya Bioscience International, Immunomedics, Gilead Sciences and National Cancer Institute of Mexico outside the submitted work.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the San Antonio Breast Cancer Symposium 2021
